The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 27, 2012
Filed:
Jul. 04, 2008
Yutaka Kondoh, Tokyo, JP;
Kazuhiko Iikubo, Tokyo, JP;
Sadao Kuromitsu, Tokyo, JP;
Nobuaki Shindo, Tokyo, JP;
Takatoshi Soga, Tokyo, JP;
Takashi Furutani, Tokyo, JP;
Itsuro Shimada, Tokyo, JP;
Takahiro Matsuya, Tokyo, JP;
Kazuo Kurosawa, Tokyo, JP;
Akio Kamikawa, Tokyo, JP;
Hiroyuki Mano, Tokyo, JP;
Yutaka Kondoh, Tokyo, JP;
Kazuhiko Iikubo, Tokyo, JP;
Sadao Kuromitsu, Tokyo, JP;
Nobuaki Shindo, Tokyo, JP;
Takatoshi Soga, Tokyo, JP;
Takashi Furutani, Tokyo, JP;
Itsuro Shimada, Tokyo, JP;
Takahiro Matsuya, Tokyo, JP;
Kazuo Kurosawa, Tokyo, JP;
Akio Kamikawa, Tokyo, JP;
Hiroyuki Mano, Tokyo, JP;
Astellas Pharma Inc., Tokyo, JP;
Abstract
The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.